contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-optomed-q4-initial-take-sales-in-line-ebit-impacted-by-a-one-off-cost

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Roche opens a DR clinic in India, but nothing is mentioned about the camera being used here.                   chennaipatrika              Chennai Patrika - Tamil Cinema News | Kollywood News | Latest Tamil Movie News...    Breaking News Stories on Tamil Cinema, Tamil Films, Tamil Movie release dates, Tamil Actors, Tamil Actresses, Tamil Directors, Tamil Producers

Kulukurssi: Can those of you who believe in the power of new CEOs and/or board members explain to a simple guy how the situation would change after a replacement? I’ve always been of the opinion that it doesn’t matter who sits in the chair, as long as it’s not consumer retail where a leader-worshipping community rushes to shop on command when the need strikes. I suppose they couldn’t change the direction anyway, because the product has approvals, obstacles have been removed, and obstacles will continue to be removed. Approvals are being sought for new products and obstacles are removed as they are identified. Explain it in very simple terms.  It matters quite a lot what kind of strategy has been formulated and how it is implemented. Perhaps with a board change, the strategy would be a notch closer to optimal, or by changing the CEO, this strategy would be implemented more optimally. I don’t know if Optomed’s strategy is the best possible one and if it is currently being implemented in the best possible way. So, I’m not here calling for changes. However, the board’s share positions are a concern. I didn’t even remember that my own stack is still larger than that of any single board member. If I remember correctly, there have been times when I had more than the entire board combined. Apparently, this position and company in my portfolio interest a small investor like me this much. Hopefully, the board is more interested. I seem to remember looking at the management team’s option programs and they looked sensible. So I believe my interests are aligned with theirs. I’m not so sure about the board.

In a company as small as Optomed, surely the CEO is the star salesperson, or at least should be when negotiating with the big US players. How about it—is he traveling to the States? I don’t know.

Management is the most important thing in a company. Always.  I bet this principle will only be reinforced in an increasingly technological world where opportunities are constantly growing. There’s your simple explanation

Can those of you who believe in the power of a new CEO and/or board members explain to a simple guy how the situation would change after a leadership swap? I’ve always been of the opinion that it doesn’t really matter who occupies the seat, as long as we aren’t talking about consumer retail where a leader-worshipping community rushes out to buy things on command whenever the urge hits. Why would a large hospital chain or healthcare provider be any more interested in the product + service than they are now, just because the management was replaced? Surely they couldn’t change the direction much anyway, since the product has its permits, hurdles have been cleared, and obstacles will continue to be cleared in the future. Permits are being sought for new products, and barriers are removed as they are identified. Break it down for me in the simplest terms possible.

The Board’s responsibilities include the company’s strategy, among other things, and the Chair leads the Board. It’s not just a job of banging the gavel and handing out speaking turns.

I guess it doesn’t matter who’s swinging the baton there​ I’m more interested in why the insiders aren’t buying the stock now while it’s “cheap”

Optomed

Redeye’s analyst just published a Research Note on Optomed.Click here to read the articleMake sure to add Optomed to your Watchlist at Redeye and our analysts will notify you if anything relevant...

<div class="mfn-body"><p>Redeye’s analyst just published a Research Note on Optomed.</p><p><strong><a rel="noopener" href="https://www.redeye.se/research/1148435/optomed-q4-initial-take-sales-in-line-ebit-impacted-by-a-one-off-cost?utm_source=MFN&amp;utm_medium=pmcour">Click here to read the article</a></strong></p><p>Make sure to add Optomed to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.</p><p>This is a press release from Redeye - Research Powered Investment Banking.&nbsp;<a rel="noopener" href="http://www.redeye.se/">www.redeye.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/3b624bb8-212f-41de-895b-3cf8a774210d/optomed-q4-initial-take-sales-in-line-ebit-impacted-by-a-one-off-cost.pdf" class="mfn-generated mfn-primary">Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost</a></p></div>